CURRENT CONCEPTS Drug-Resistant Epilepsy

Grants

Funding Acknowledgements

Dr. Brodie reports receiving consulting fees from Eisai, lecture fees from GlaxoSmithKline, UCB Pharma, Eisai, Novartis, and Medtronic, travel accommodations paid by UCB Pharma, and grant support to his institution from UCB Pharma and Eisai. Dr. Kwan reports receiving consulting fees from Pfizer, lecture fees from Eisai, and travel accommodations paid by UCB Pharma; he also holds a patent related to a rapid HLA typing method (PCT/CN2009/074891), and his institution has received grant support from Eisai, Johnson & Johnson, Pfizer, and UCB Pharma. Dr. Schachter reports receiving consulting fees from Marinus Pharmaceuticals, NeuroTherapeutics Pharma, Sepracor, BrainScope, and Cyberonics, lecture fees from Elsevier and Pri-Med, and payment for serving on a data and safety monitoring board from Quintiles and AXIS Healthcare Communications; he also holds patents related to seizure-detection algorithms and huperzine as a treatment for epilepsy (20100234416, 20060264455, and 20060111644). No other potential conflict of interest relevant to this article was reported.